Vivani Medical's Bold Move Towards Innovation
Cortigent is making waves in the field of brain implant technologies, establishing itself as a pioneer in precision neurostimulation. Notably, it stands as the sole developer with FDA approval for a device that delivers artificial vision to profoundly blind individuals.
A Mission to Transform Lives
The Cortigent Orion artificial vision system represents a groundbreaking advancement aimed at treating blindness resulting from common medical conditions. After a successful six-year Early Feasibility Study, this innovative device showcases promising capabilities in restoring vision.
The Spin-off: A Strategic Opportunity
Vivani Medical, Inc. (NASDAQ: VANI), a clinical-stage biopharmaceutical company known for its pioneering drug delivery systems, has announced that it is moving forward with a planned spin-off of Cortigent, its specialized subsidiary. This decision is set to amplify both companies' focus on their unique areas of innovation.
Shareholders of Vivani who are on record by October 8, 2025, will be entitled to shares in Cortigent. The company is gearing up to be listed on the Nasdaq under the ticker symbol “CRGT”, pending regulatory approvals. The specific distribution timeline and share allocation will be disclosed later.
Shared Vision and Growth Potential
As Vivani's CEO Adam Mendelsohn noted, this spin-off is a strategic move aimed at creating two companies that are more agile and focused in their domains. By establishing Cortigent as an independently traded company, Vivani shareholders will have a direct stake in Cortigent's advancements in the field of neurostimulation technology.
Cortigent's Future Path
Cortigent's CEO, Jonathan Adams, emphasizes the spin-off's potential to streamline operations and dedicate resources towards innovative research. This new chapter aims to position Cortigent at the forefront of the neuromodulation arena, a field that utilizes the latest advances in artificial intelligence to fulfill significant medical needs.
The immediate next steps after the spin-off include initiating the planned pivotal clinical trial for the Orion system, which aims to secure FDA approval. Additionally, Cortigent will commence its Early Feasibility Study focused on its Stroke Recovery System, enhancing its commitment to addressing critical health challenges.
Enhancing Operational Flexibility
The anticipated benefits of Cortigent's spin-off are considerable. Both companies will have the flexibility to execute their business strategies without the constraints typically associated with shared operations. This approach will allow for better capital structuring and drive growth opportunities through acquisitions and partnerships.
Investing in Neuromodulation Technology
Once publicly traded, Cortigent will provide a unique investment opportunity for stakeholders interested in pioneering developments within the biotechnological framework. With a rich history of success in transforming patient healthcare outcomes, the company aims to build upon its technological successes and continue its impactful narrative.
Adams, who has been steering Cortigent since March 2023, will maintain his leadership role post-spin-off as they remain headquartered in the Los Angeles area. Vivani will support Cortigent during this transition phase to ensure a smooth operational handover.
Timeline and Regulatory Framework
Plans for the spin-off are slated for completion in late 2025, contingent upon fulfilling several regulatory conditions. These involve procuring a favorable tax opinion and finalizing a registration statement with the U.S. Securities and Exchange Commission.
This spin-off represents a significant milestone in the evolution of both Vivani Medical and Cortigent, enhancing shareholder value and fostering a new wave of medical innovation.
Frequently Asked Questions
What is the focus of the spin-off company, Cortigent?
Cortigent focuses on developing advanced brain implant devices utilizing neurostimulation technology to help patients recover critical body functions.
When is the expected completion date for the Cortigent spin-off?
The spin-off is anticipated to be finalized by late 2025, depending on several regulatory conditions.
What will Vivani's investors receive from the spin-off?
Vivani investors holding shares as of the record date will receive shares in Cortigent, facilitating direct investment in its innovations.
How will the spin-off benefit both companies?
The spin-off allows each company to focus on their respective strategies and streamlines operations for better growth prospects.
What is the mission of Vivani Medical?
Vivani Medical aims to leverage its innovative drug delivery systems to offer extended-release biopharmaceutical implants, enhancing patient adherence to medications.
